Uridine diphospho-glucuronosyltransferases (UGTs) inactivate and facilitate the excretion of estrogens to glucuronides (-G), the most abundant circulating estrogen conjugates. The identity of the conjugated estrogens formed by all known overexpressed UGTs (n ‫؍‬ 16) was analyzed by comparison with retention time and mass fragmentation of authentic standards by HPLC tandem mass spectrometry methods. Six UGTs, namely 1A1, 1A3, 1A8, 1A9, 1A10, and 2B7, were found to glucuronidate estradiol (E 2 ) and estrone (E 1 ), their hydroxyls (OH), and their methoxy derivatives (MeO). Addition of glucuronic acid was catalyzed by specific UGTs at positions 2, 3, and 4 of the estrogens, whereas only E 2 was conjugated at position 17 by UGT2B7. Kinetic parameters indicate that the conjugation of E 2 at position 3 was predominantly catalyzed by 1A1, 1A3, and 1A8 and by 1A8 for E 1 . Conjugation of 2-OHE 1 /E 2 and 2-and 4-MeOE 1 /E 2 was selective at position 3, mostly catalyzed by 1A1 and 1A8. Of all UGTs, UGT2B7 demonstrated the highest catalytic activities for estrogens and at least 10-to 50-fold higher activity for the conjugation of geno- E XPOSURE OF ESTROGEN-SENSITIVE tissues to excessive stimulation by natural or synthetic estrogens is considered as a significant factor in the induction and the development of cancers (1, 2). As a key determinant in estrogen action, the intracellular concentration of estrogens is dependent not only on circulating estrogen levels but also on in situ or intracrine formation and local metabolism in estrogen-sensitive tissues (3, 4). A number of studies have clearly demonstrated that estrogen target tissues are the site of modification of estrogen action through conversion of estrogens into the hydroxylated derivatives catechol estrogens (CEs) by cytochromes P450 (CYP), which mainly oxidize estrogen into 2-hydroxy-CE [2-OH-estrone (E 1 )/estradiol (E 2 )] and 4-hydroxy-CE (4-OHE 1 /E 2 ), and the catechol-O-methyltransferase (COMT) that converts CEs to methyl-CE (MeOCEs) (5, 6).
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E XPOSURE OF ESTROGEN-SENSITIVE tissues to excessive stimulation by natural or synthetic estrogens is considered as a significant factor in the induction and the development of cancers (1, 2) . As a key determinant in estrogen action, the intracellular concentration of estrogens is dependent not only on circulating estrogen levels but also on in situ or intracrine formation and local metabolism in estrogen-sensitive tissues (3, 4) . A number of studies have clearly demonstrated that estrogen target tissues are the site of modification of estrogen action through conversion of estrogens into the hydroxylated derivatives catechol estrogens (CEs) by cytochromes P450 (CYP), which mainly oxidize estrogen into 2-hydroxy-CE [2-OH-estrone (E 1 )/estradiol (E 2 )] and 4-hydroxy-CE (4-OHE 1 /E 2 ), and the catechol-O-methyltransferase (COMT) that converts CEs to methyl-CE (MeOCEs) (5, 6) .
Recent findings highlight the importance of CE metabolites as chemical mediators and their link to cancer development and progression (7) (8) (9) . For instance, 4-OHE 2 undergoes metabolic redox cycling to generate reactive oxygen species, which may damage lipids and DNA and initiate estrogen-related carcinogenesis (10) . By contrast, biotransformation of CE to 2-MeOCE may result in the formation of a protective metabolite having very potent inhibitory effect on cell proliferation, tubulin activity, and angiogenesis (11) (12) (13) . The formation of CEs and MeOCEs may proceed through reactions carried out by hepatic metabolism but also through local metabolic conversion in extrahepatic hormone responsive organs or through a combination of both. Because of their unique chemical and biological properties, it is critical to establish the contribution of extrahepatic formation and elimination of estrogen and of their metabolites.
Conjugation transforms estrogenic hormones into less active, more polar and water-soluble metabolites, thus facilitating their excretion in the bile and urine. Conjugative estrogen metabolism includes sulfonation (14) and glucu-ronidation (15) (16) (17) (18) , two reactions catalyzed by sulfotransferases and uridine diphospho-glucuronosyltransferases (UGTs), respectively. In fact, sulfates and glucuronides are the most abundant circulating estrogen conjugates (19) , whereas estrogen sulfates represent a form of estrogen storage that acts as a precursor of E 2 (14) . On the other hand, glucuronidation by UGTs leads to complete inactivation of estrogen (17, 19) . To the best of our knowledge, human ␤-glucuronidase activity has never been reported in the literature for the endometrium. Glucuronidation of steroids is not limited to the liver, and this metabolic pathway is recognized as contributing significantly to the modulation of specific physiological effects of steroids in target tissues such as the prostate (15, 20 -22) . Furthermore, the detection of significant amounts of estrogen glucuronides in the breast cystic fluid supports the role of the glucuronidation metabolism in the elimination of estrogens (23, 24) . The presence of UGTs was reported in several estrogen target organs such as the breast and uterus (15, 25, 26) , even though a comprehensive analysis of the expression of every UGT enzyme reactive toward estrogens in target tissues has never been completed. Several human UGTs are known to exert catalytic activities toward E 2 , E 1 , and their hydroxylated metabolites, whereas the glucuronidation of MeOCE remains to be clarified (17, 18, (27) (28) (29) (30) . To date, 16 functional UGT proteins have been reported (31, 32) . In vitro studies using human UGT cDNAs cloned and expressed in mammalian cells have been used to determine the specificity of UGT isoenzymes for some estrogens in a small number of studies (15, 17, 18, 28 -30) , whereas a systematic study using the same experimental conditions remains to be conducted. The detailed regioselectivity of UGTs has never been systematically established, possibly because of the lack of estrogen glucuronide standards and suitable analytical methods.
In the present study, we hypothesized that E 2 , E 1 , and their oxidatized metabolites undergo glucuronidation at various positions and that these site-specific reactions are catalyzed by different UGTs. Given that the enzymatic machinery for the formation of catechol and methoxy metabolites of estrogen was demonstrated in the uterus (5, 6) , it was expected that UGT involved in the glucuronidation of estrogen would also be expressed. We have first developed a highly sensitive and specific mass spectrometry-based analytical method to thoroughly establish the substrate specificity and stereoselectivity of all known functional human UGT proteins toward E 2 and E 1 and their hydroxyl as well as their MeOCE derivatives under the same experimental conditions. In the course of this study, we accumulated data on the enzymatic kinetics [maximal velocity (V max ), substrate concentration at half-maximal velocity (K m ), and catalytic efficiencies] of individual UGT isoforms to determine which UGTs are the most efficient in catalyzing glucuronidation at the 2-, 3-, 4-, and 17-hydroxyl positions of estrogens and define their stereoselectivity. Subsequently we explored the expression of UGT2B7 that metabolizes with the highest catalytic efficiency the genotoxic 4-OHCEs in the uterus by RT-PCR and immunohistochemistry using a specific antibody. Altogether, the data indicate that glucuronidation of estrogen may be one of the mechanisms of major biological significance in the inactivation and elimination of estrogens, their reactive CEs, and MeOCE metabolites in the uterus. were synthesized by Endorecherche (Québec, Canada), and confirmation of the structure of each product was determined by nuclear magnetic resonance. Methanol (HPLC grade), acetonitrile (HPLC grade), 1-chlorobutane (HPLC grade), and iso-amyl-alcohol were obtained from VWR Canlab (Montréal, Canada). Ammonium hydroxide (trace metal grade) was purchased from Fisher Scientific (Nepean, Canada).
Materials and Methods

Characterization of human embryonic kidney (HEK)293 cell systems expressing UGT1A and UGT2B
Microsomal proteins used for UGT expression were prepared as previously described (33) (34) (35) . To ascertain the level of UGT protein expression in the stable UGT1A-and UGT2B-HEK293 clones, a semiquantitative immunoblot analysis method was used. The microsomal fractions from UGT-HEK293 cells were used in all enzymatic assays, whereas in the case of UGT1A10, commercial microsomal fractions of Sf-9 insect cells infected with a baculovirus strain containing human UGT1A10 cDNA were used (Panvera, Madison, WI). Microsomal proteins (10 g protein) were separated on SDS-PAGE and transferred onto nitrocellulose. For quantification of the UGT1A proteins, we used the antihuman UGT1A common carboxyl terminus region (amino acids 312-531) antiserum RC-71, as previously reported (15, 34, 35) . UGT2B protein levels were quantified using the antihuman UGT2B antibody (EL-93), as previously described (36) . To normalize sample loading, blots were stripped and reprobed with anticalnexin antibody (Stressgen Biotechnologies, Victoria, Canada) to detect a second endoplasmic reticulum-resident protein, calnexin. Bands were visualized using enhanced chemiluminescence (Amersham, Piscataway, NJ) and quantified by Bioimage Visage 110s from Genomic Solutions Inc. (Ann Arbor, MI). Ratios between UGT and calnexin signals were calculated for each UGT except for UGT1A10 baculosome for which the UGT signal alone was considered for the expression level.
Assay of UGT activity
Microsomal fractions from UGT-HEK293 cells and commercial microsomal fraction of UGT1A10 were used in enzymatic assays. Reactions (100 l volume) contained 50 mm Tris-HCl (pH.7.5), 10 mm MgCl 2 , 100 g/ml phosphatidylcholine, 8.5 mm saccharolactone, 2 mm uridine diphospho-glucuronic acid, and 40 -60 g membrane protein and steroid substrate (25 m). Reactions were initiated by adding varying concentrations of each individual substrate. Blanks and controls contained all compounds except steroid substrates and microsomal preparation, respectively. The assays were terminated by adding 100 l methanol and were centrifuged at 14,000 ϫ g for 10 min before analysis. Time-course experiments were designed to determine the linearity of the glucuronidation reaction. All reaction rates were shown to be linear under the selected time interval, and inclusion of detergent was found to be unnecessary for assessment of the full glucuronidating potential of UGT-expressing HEK cell membranes. For determination of V max and K m values, HEK293 cells stably expressing UGT enzymes were incubated in the presence of varying substrate concentrations from 0.5 to 200 m for 1 h. Absolute glucuronidation activities were divided by the level of UGT protein and expressed as relative glucuronidation activities in picomoles per minute per milligram.
Mass spectrometry analysis
Incubation medium was diluted with 0.1 ml methanol/water (50:50; vol/vol), vortexed, and then transferred into a conical vial for injection into the mass spectrometer. The HPLC and tandem mass spectrometry (MS/MS) system consisted of a mass spectrometer (model API 3000, Perkin-Elmer Sciex, Thornhill, Canada) equipped with an elecrospray ionization source in the negative ion mode and a HPLC pump plus autosampler (model 2690, Waters, Milford, MA). A chromatographic separation was achieved with a 100 ϫ 3.9 mm Xterra MS C 8 column 3.5 m packing material (Waters), using a three-solvent isocratic system (A: water ϩ 0.1% ammonium hydroxide; B: methanol ϩ 0.1% ammonium hydroxide; C: acetonitrile ϩ 0.1% ammonium hydroxide) at a constant flow rate (0.8 ml/min) for 8 min with 90% A, 8.5% B, and 1.5% C. Afterward, the column was washed with 93.5% B and then reequilibrated to initial conditions over 4 min. The mass spectrometer was operated in the multiple reaction monitoring (MRM) mode, and the quantification of the products formed was performed using a calibration curve in the range of 200 -10,000 pg/ml of incubation medium for each substrate.
Tissue procurement, RNA purification, reverse transcription, and expression analyses
Nonmalignant uterine tissue was obtained from postmenopausal women who had not received hormone replacement therapy for at least 3 wk and who had no menstrual bleeding for at least 1 yr. All subjects provided written consent for use of their specimens, and the present study was reviewed and approved by Institutional Review Boards (Hô tel-Dieu de Québec, Centre Hospitalier de l'Université Laval Research Center, and Laval University). Fresh material from patients were all collected by the pathologist and immediately deposited in liquid nitrogen within 30 min of surgery pending transfer to a freezer at Ϫ80 C. RNA was isolated by the acid guanidium thiocyanate/chloroform method (37) . Total RNA was collected with Trizol (Molecular Research Center, Cincinnati, OH), and random hexamers (pDN6) were used to synthesize cDNA from total RNA (1 g) using a SuperScript II cDNA synthesis kit (Invitrogen, Carlsbad, CA) according to the manufacturer's specifications. Semiquantitative RT-PCR was used to study the expression of the UGT2B7 gene using primers 882 forward: 5Ј-ctacgtacctgttgttatgtcagaattaac and 883 reverse: 5Ј-actgatcccacttcttcatgtcaa. For amplification of glyceraldehyde-3-phosphate dehydrogenase (GAPDH), these primers were used: 41 forward: 5Ј-tgggtgtgaaccatgag and 42 reverse: 5Ј-cccagcgtcaaaggtgg. PCR products were sequenced. All PCR amplifications were performed using Taq DNA polymerase at 95 C, 30 sec for denaturation, 59 C, 40 sec for annealing, and 72 C, 45 sec for extension in a thermal cycler, with a fixed number of 35 cycles for each pair of primers. GAPDH was used as internal standard.
Characterization of the polyclonal anti-UGT2B7 antibody
Anti-UGT2B7 antibody was raised against amino acids 55-164 (110 amino acids length) of the protein. This fragment corresponds to the portion of the UGT2B7 protein that is the least homologous to other human UGT2B. Several rabbits were injected with a total of 100 g purified fusion proteins in the presence of incomplete Freund's adjuvant. The production of antibodies was determined 12 d after the injections. To gain information concerning the novel anti-UGT2B7 antibody, Western blot experiments using the recombinant UGT2B7 protein fragment and microsomal proteins from UGT2B7-HK293 cells showed that the immune serum 1809 is immunoreactive for UGT2B7. The specificity of the anti-UGT2B7 1809 antibody was studied by Western blot experiments using microsomal proteins (10 g) of HK293 cells stably expressing all known UGT2B subfamily members, namely UGT2B4, 2B7, 2B10, 2B11, 2B15, 2B17, and 2B28. Microsomal proteins of human liver were used as positive control. The gel was transferred onto nitrocellulose membrane and incubated with anti-UGT2B7 1809 antibody (dilution 1:2000). Bands were visualized using enhanced chemiluminescence (Amersham) and quantified by Bioimage Visage 110s (Genomic Solutions).
Immunohistochemistry
Six nonmalignant human uterine tissues were also fixed in formol and embedded in paraffin for immunohistochemical studies. The tissues were serially cut at 5-m and sections mounted on glass slides. The sections were deparaffinized, hydrated, and incubated overnight at 4 C with the human UGT2B7 antiserum diluted 1:250 in Tris-saline (pH 7.6). The sections were then washed and incubated at room temperature for 4 h with peroxidase-conjugated goat antirabbit immunoglobulins (DakoCytomation, Glostrup, Denmark) diluted 1:200 as previously described (38) . Endogenous peroxidase activity was eliminated by preincubation with 3% H 2 O 2 for 30 min, and peroxidase was then revealed during incubation with 15 mg of 3,3Ј-diaminobenzidine in 100 ml Trissaline buffer containing 0.03% H 2 O 2 . The intensity of the staining was controlled under the microscope. The sections were then counterstained with hematoxylin. Control experiments were performed on adjacent sections by substituting preimmune rabbit serum (1:250).
Enzyme kinetic analysis
Visual inspection of fitted functions [velocity as a function of substrate concentration] and Eadie-Hofstee plots [velocity as a function of (velocity/substrate concentration)] was used to select the best fit enzyme kinetic model (39) . These include the Michaelis-Menten
where n is the Hill coefficient or the degree of curve sigmoidicity, and K s is an inhibition constant. Analysis of data showing sigmoid kinetic was performed using SigmaPlot 8.0 with Enzyme Kinetics 1.1 (SPSS, Chicago, IL), and analysis of data showing substrate inhibition or Michaelis-Menten kinetics was performed using Enzfitter (Biosoft, Ferguson, MO). For Michaelis-Menten and substrate inhibition models, the intrinsic clearance (CL int ) estimation values were calculated based on the following equation: CL int ϭ V max /K m , whereas for sigmoid model the maximal clearance (CL max ) estimation values were calculated using the following equation:
Results
Analysis of the glucuronidated estrogens by MS
The identity of all conjugated products formed by expressed UGTs was confirmed by comparison with the retention time of HPLC and mass fragmentation of authentic standards using HPLC and tandem MS (MS/MS) methods developed to specifically detect and quantify the E glucuronides. The analyses of those compounds by MS/MS were assessed by MRM mode (parent and daughter ion) to provide higher specificity than single ion monitoring ( Table 1 ). The high accuracy of this analytical method is also achieved by the quality of the chromatographic separation achieved between the two glucuronide products potentially formed from each individual 2-OHCEs and 4-OHCEs. As illustrated in Fig. 1A , despite the same parent and daughter ions for 2-OHE 2 -2G and 2-OHE 2 -3G, it was possible to chromatographically separate the two estrogen glucuronides. Good chromatographic resolution was also obtained for 4-OHE 2 -4G and 4-OHE 2 -3G, which also have the same ions (Fig. 1B) .
Enzymatic specificity of human UGT enzymes for estrogens
Assays of human UGTs toward a series of estrogens, namely E 1 , E 2 , 2-OHE 1 /E 2 , 4-OHE 1 /E 2 , and their methoxy derivatives 2-MeOE 1 /E 2 and 4-MeOE 1 /E 2 , were performed using microsomal preparations of HK293 cells engineered to stably express all known human UGTs, with the exception of UGT1A10, which was overexpressed in baculosomes.
The initial screening of the conjugating activity was performed by incubation with the selected microsomal preparation for 16 h containing 25 m of the estrogenic substrate and 1 mm of glucuronic acid. Most of the UGT2B isoenzymes did not catalyze the glucuronidation of estrogens, except UGT2B7, whereas UGT2B4's activity was minimal ( Table 2) . On the other hand, several UGT1As were capable of conjugating estrogens with high efficiency, namely UGT1A1, UGT1A3, UGT1A8, UGT1A9, and UGT1A10 ( Table 2 ). The formation of glucuronidated products at positions 2, 3, and 4 of hydroxylated E 2 /E 1 was achieved by several UGT isoforms, whereas conjugation at position 17 of 2-and 4-hydroxylated E 2 could not be detected (data not shown).
UGTs with a significant reactivity for at least one of the estrogenic substrates were assayed in further details to determine kinetic parameters (apparent K m , relative V max , and catalytic efficiencies) ( Table 3) . The values of apparent K m and relative V max presented are from one experiment performed in duplicate. Kinetics were repeated for most of the substrates and similar results were obtained in independent experiments. On visual inspection of fitted functions and Eadie-Hofstee plots to select the best fit enzyme kinetic model (39) among Michaelis-Menten, substrate activation, and uncompetitive substrate inhibition, kinetic parameters were calculated using equations described in Materials and Methods. The detailed experimentation has allowed us to delineate kinetic properties of UGTs toward estrogens. Various enzymatic kinetic profiles were observed depending on the substrate, especially for E 1 , E 2 , and 2-OHCEs, and also depending on the products formed as well as the position to which the glucuronic acid is transferred. Similar reports of atypical kinetic properties of human UGTs have recently been published (41, 42) .
Glucuronidation of E 2 and E 1
UGT1A1, UGT1A3, UGT1A8, and UGT1A10 conjugate both E 2 and E 1 , whereas UGT2B7 and UGT1A9 glucuronidate specifically E 2 and E 1 , respectively (Table 3) . Conjugation of E 2 was exclusively at position 3 for all UGTs tested, except for UGT2B7, which glucuronidated E 2 at position 17 and to a lesser extent by UGT1A3. K m values for the formation of E 2 -3G and E 2 -17G were almost in the same range varying from 10 to 47 m, whereas higher K m values were observed for E 1 -3G (38 -90 m). In general, lower velocity was observed for E 1 -3G, compared with E 2 -3G and E 2 -17G conjugation, with the exception of UGT1A8, which demonstrated the highest V max for both E 1 -3G (142 pmol/min⅐mg) and E 2 -3G (195 pmol/min⅐mg).
Depending on which UGT was involved, glucuronidation of E 1 and E 2 followed sigmoid and hyperbolic kinetic profiles (Fig. 2) . Data for UGT1A1 and UGT1A3 best fitted a sigmoid profile for E 1 and E 2 , and UGT1A9 and UGT2B7 exhibited hyperbolic profiles for the conjugation of E 1 and E 2 . In turns, UGT1A8 and UGT1A10 demonstrated a kinetic profile dependent of the estrogenic substrate with a hyperbolic profile for E 2 and a sigmoid profile for E 1 .
Catalytic efficiency values for the formation of E 2 -3G and E 2 -17G varied from 0.2 to 5.1 l/min⅐mg, with UGT1A8 and UGT2B7 being the most efficient at glucuronidating E 2 -3G and E 2 -17G, respectively ( Table 3 ). The highest value of catalytic efficiency was observed for E 1 -3G with UGT1A8 (1.3 l/min⅐mg).
Glucuronidation of 2-OHCE
Five UGTs, namely UGT1A1, UGT1A3, UGT1A8, UGT1A9, and UGT2B7, are responsible for the conjugation of 2-OHE 2 and 2-OHE 1 with the exception of UGT2B7, which shows activity for only 2-OHE 2 . Although position 17 of 2-OHE 2 is not glucuronidated by UGTs (data not shown), every reactive UGT toward 2-OHCEs conjugates hydroxyls at both positions 2 and 3, except UGT1A1, which demonstrates a regioselective activity for the glucuronidation of . The MS was operated in the MRM mode with mass of 463 and 287 for 2-OHE 2 -2G and 2-OHE 2 -3G and monitoring of mass 463 and 287 for 4-OHE 2 -4G and 4-OHE 2 -3G. The chromatographic separation was achieved with a 100 ϫ 3.9-mm Xterra MS C 8 column 3.5-m packing material, using a three-solvent isocratic system as described in Materials and Methods.
2-OHE 2 at position 2 and not for 2-OHE 1 at the same position (Table 3) .
Glucuronidation of 2-OHCEs by UGT1A1, UGT1A3, and UGT1A8 display hyperbolic, sigmoid, or substrate inhibition profiles, whereas glucuronidation of 2-OHCEs by UGT1A9 and UGT2B7 follows a hyperbolic profile for both positions of 2-OHCEs (Fig. 3, A and B) . The values of apparent K m for conjugation at positions 2 or 3 of 2-OHE 2 vary widely, from 15 to 479 m, whereas the K m values are slightly higher for 2-OHE 1 , especially at position 3, with UGT1A3 having a K m of 587 m (Table 3 ). In fact, the catalytic efficiencies of 2-OHE 2 conjugation by UGT1A8 and UGT2B7 are markedly higher than those of UGT1A1, UGT1A3, and UGT1A9. In fact, the catalytic efficiencies are as high as 11.3 l/min⅐mg protein for glucuronidation at position 3-hydroxy of 2-OHE 2 by UGT2B7. Values are approximately 10-fold lower for conjugation at position 2-hydroxy, with the highest being at 1.3 l/min⅐mg protein. On the other hand, the values of the catalytic efficiencies are similar for all enzymes in the conjugation of 2-OHE 1 , with the exception of UGT1A1, which is much more efficient at conjugating 2-OHE 1 at position 3 (Table 3) .
In summary, our data indicate that UGT2B7, UGT1A8, and UGT1A1 are the predominant conjugating enzymes of 2-OHE 2 , whereas UGT1A1 is the major enzyme involved in 2-OHE 1 -3G formation. It is important to note that all isoforms preferentially conjugate the 3-hydroxy of 2-OHCE.
Glucuronidation of 4-OHCE
As observed for 2-OHE 1 /E 2 , 4-OHE 1 /E 2 can be conjugated in the two hydroxylated positions of ring A of the estrogen, whereas position 17 remains not conjugated (data not shown). For both 4-OHE 2 and 4-OHE 1 , UGT1A1, UGT1A8, UGT1A9, and UGT2B7 have significant conjugating activities. In contrast to what was observed for 2-OHCEs, glucuronidation of 4-OHCEs by UGTs exhibits an hyperbolic profile, except for UGT1A1, which demonstrates substrate inhibition and sigmoid profiles for conjugation of both hydroxylated positions of 4-OHE 2 and 4-OHE 1 , respectively (Fig. 3, C and D) .
The K m values for the 3 and 4 positions of 4-OHE 2 ranged from 38 to 118 m, except UGT2B7, which has much higher affinity for 4-OHE 2 with K m values of 10 and 22 m at positions 4 and 3, respectively ( Table 3 ). The catalytic efficiency of 4-OHE 1 glucuronidation at position 3 by the UGT isoforms appears relatively low, compared with conjugation of the same molecule at position 4. Two isoforms are major in the conjugation of position 4 of 4-OHE 2 , namely UGT1A8 and UGT2B7, which demonstrate two of the highest V max values observed, 4723 and 5235 pmol/min⅐mg, respectively. Although the conjugation of 4-OHE 1 was lower, compared with 4-OHE 2 , UGT2B7 demonstrates the highest V max at 8724 pmol/min⅐mg. The catalytic efficiency of UGT2B7 was about 5-fold higher for 4-OHE 2 (523.5 l/min⅐mg protein), compared with 4-OHE 1 (140.7 l/min⅐mg protein). Conjugation at the 3 hydroxyl position of 4-OHCE is preferentially catalyzed by UGT1A8, whereas the predominant substrate is 4-OHE 1 . The relative V max of 1975 pmol/min⅐mg and the catalytic efficiency of 10.7 l/min⅐mg protein for UGT1A8 are at least 10-fold higher than the other UGTs catalyzing 4-OHE 2 -3G and 4-OHE 1 -3G. It is concluded that 4-OHE 1 is predominantly conjugated at position 4 by UGT2B7, whereas for 4-OHE 2 , UGT1A8 and UGT2B7 are the predominant isoforms involved in the conjugation at position 4 ( Table 3) .
Glucuronidation of 2-MeOCE and 4-MeOCE
Our data demonstrate that five UGTs, namely UGT1A1, UGT1A3, UGT1A8, UGT1A9, and UGT1A10, conjugate 2-MeOCE. Of them, only UGT1A1 and UGT1A8 conjugate 4-MeOCE. As observed for other hydroxylated E, position 17 2G  3G  2G  3G  3G  4G  3G  4G  3G  3G  3G  3G 1A1
Ϫ, Negligible; (ϩ), 101-500 ng/ml; ϩ, 501-1,000 ng/ml; ϩϩ, 1,001-5,000 ng/ml; ϩϩϩ, 5,001-10,000 ng/ml; ϩϩϩϩ, up to 10,000 ng/ml; LOQ, limit of quantification (ng/ml).
was not conjugated. All UGTs displayed a hyperbolic kinetic profile (curves not shown).
Glucuronidation of 2-and 4-MeOE 2 occurs at higher rates than for 2-and 4-MeOE 1 , these reactions being mostly 14, and 8 m, respectively ( Table 3 ). The catalytic efficiencies of 4-MeOE 2 and 2-MeOE 2 /E 1 by UGT1A8 were the highest at 27.3, 15.9, and 10.9 l/min⅐mg protein, respectively. UGT1A1 and UGT1A3 were also efficient at conjugating 2-MeOE 2 with catalytic efficiencies of 4.5 and 3.1 l/min⅐mg protein, respectively.
Specificity of the polyclonal anti-UGT2B7 antibody
Western blot analysis using microsomal proteins (10 g) of HK293 cells and HK293 cells stably expressing UGT2B4, 2B7, 2B10, 2B11, 2B15, 2B17, and 2B28 revealed that anti-UGT2B7 1809 antibody is specific to UGT2B7 protein. Microsomal proteins of human liver were used as positive control (Fig. 4A) .
Expression of UGT2B7 in the uterus
The expression of the UGT2B7 was first assessed in endometrial tissues collected from six postmenopausal women by RT-PCR. Significant variation in UGT2B7 transcripts between endometrial samples was evident (Fig. 5) . Immunostaining using specific antibodies to human UGT2B7 showed the presence of immunoreactive material in nonmalignant endometrium and myometrium. Both epithelial cells lining the glands and those covering the surface were strongly reactive (Fig. 4B) . Endometrial stromal cells were also immunoreactive (Fig. 4B) . In the myometrium, the vast majority of smooth muscle cells exhibited moderate immunolabeling (Fig. 4C) . When the nonimmune serum was used, no staining could be detected (data not shown).
Discussion
In the present study, we thoroughly characterized the conjugation of E 2 and its main metabolites by all known human UGT enzymes. A newly developed HPLC/MS/MS method was used to accurately and specifically determine the products formed. The initial metabolic screening analyses show that a limited number of UGTs are capable of conjugating E 2 ; E 1 ; their hydroxylated metabolites, 2-OHCEs and 4-OHCEs; and their methoxyestrogen metabolites. Data indicate that the addition of the glucuronic acid is possible at positions 2, 3, and 4 of the catechol estrogens, whereas of all estrogens tested, only E 2 was conjugated at position 17 (Fig. 6 ). Detailed kinetic analyses point out that only six UGT enzymes of all 16 tested are involved in this process, namely UGT1A1, UGT1A3, UGT1A8, UGT1A9, UGT1A10, and UGT2B7, whereas a limited number of UGTs display regioselectivity for the estrogenic molecules. The data further indicate that UGT2B7, the most reactive UGT toward the genotoxic 4-OHCEs, is expressed at variable levels in endometrial tissue of postmenopausal women, even though the sample size was limited. Our observations support the concept that E 1 and E 2 and their metabolites formed locally in estrogen sensitive tissues (5, 6) are conjugated by specific UGT enzymes in situ to achieve complete inactivation before their release in the circulation. The data further suggest a potential biological role of this metabolic pathway in the inactivation of genotoxic estrogens and that UGT2B7 is a key player in this process.
Compelling evidences that support glucuronidation as a major pathway of steroid inactivation and elimination in the liver and a number of steroid sensitive tissues have been published. For androgens, previous observations have clearly demonstrated the major role played by specific UGT2B isoenzymes, namely UGT2B7, UGT2B15, and UGT2B17, and their remarkable regioselectivity in the conjugation at positions 3 and/or 17 of dihydrotestosterone and its two major metabolites, and rostane-3␣, 17␤-diol, and androsterone (22) . Although less attention was given to estrogen glucuronidation, few studies indicated that E 1 and E 2 may also be conjugated by specific UGTs in estrogen-sensitive tissues (15, 25, 33, 43, 44) . Besides, E 1 and E 2 are converted into multiple hydroxylated metabolites in not only the liver but also several peripheral tissues (3).
Recently Lee et al. (45) conducted a study aimed at characterizing the major metabolites of E 1 and E 2 by selected human CYPs. The authors concluded that the main oxidative pathway of E 1 and E 2 is likely by CYP1A1, CYP3A4, and CYP1B1, which predominantly leads to catechol estrogen production. In fact, CYP1A1 and CYP3A4 are responsible for the production of 2-OHCE and are expressed in estrogen-sensitive tissues, including the endometrium. CYP1B1 is exclusively found in extrahepatic tissues, namely the breast and endometrium, and produces 4-OHCE (5, 46, 47) . These observations are concurrent with the recent findings of Rogan et al. (48) , who demonstrated substantial amounts of CEs and their methoxyestrogen derivatives in breast tissue. However, in that study, the measurements of estrogen metabolites in the tissue were performed after treatment of the homogenate extracts with ␤-glucuronidase, thus indicating the potential for local formation of polar glucuronide derivatives. In fact, earlier studies demonstrated high concentrations of E 1 and E 2 glucuronides in the breast cyst fluid (23, 24) , which is supported by the expression of several UGT isoenzymes (25, 33) . The present findings suggest the formation of estrogen glucuronide derivatives in a second estrogen-sensitive tissue, namely the endometrium. As demonstrated recently for CYPs (45) , human UGTs catalyze the transfer of glucuronic acid to estrogenic substrates with a large range of catalytic efficiency and a unique stereoselectivity (Fig. 6) . Even though more than one UGT is frequently involved in the conjugation of various estrogens, data indicate that several UGTs possess a distinctive regioselectivity for specific estrogenic molecules. The first general observation derived from our metabolic studies is that UGT1A family members conjugate estrogens at positions 2, 3, and 4 but not at position 17, with the exception of UGT1A3, which, however, shows a very low catalytic efficiency for this position. Previous observations have already indicated that UGT2B7 exclusively conjugates E 2 at position 17, whereas UGT1A1 was the enzyme responsible for the glucuronidation at position 3 (18, 28, 29) . However, the present data clearly show that UGT1A8 is the predominant enzyme for conjugation of E 2 at position 3 followed by UGT1A1. The data further reveal that E 2 is the preferred estrogenic substrate for glucuronidation by human UGTs, compared with its keto metabolite E 1 . This affirmation is also true for their corresponding 2-OHE 1 /E 2 , 4-OHE 1 /E 2 , and 4-MeOE 1 /E 2 derivatives.
It is believed that the polarity of the estrogenic substrate has an important role in the subsequent conjugation via the glucuronidation pathway. Additional examination of data indicates that the glucuronidation of 2-OHE 2 and 2-OHE 1 is in large part at position 3 and that this conjugation is performed by UGT1A1, UGT1A8, and UGT2B7, whereas a modest activity is also observed for UGT1A3 and UGT1A9. In contrast, 4-OHE 2 and 4-OHE 1 are conjugated predominantly at position 4 and UGT2B7 is the major enzyme involved. In fact, it is the first time that the glucuronidation at position 4 of 4-OHE 2 /E 1 is observed. Based on the in vitro enzyme kinetic data, the inactivation of 4-OHCEs is catalyzed by several enzymes but largely by UGT2B7. As previously observed for other estrogen metabolites, the change of the hydroxy group (E 2 ) to the keto group (E 1 ) at position 17 reduces by more than 50% the efficiency of UGT2B7. Recently Gestl et al. (25) have shown that the expression of UGT2B7 is particularly decreased in cancerous mammary gland tissue, compared with normal tissue. These authors suggested that UGT2B7 would protect the mammary gland from the genotoxic estrogen 4-OHE 1 . Our data support the involvement of UGT2B7 in the inactivation of 4-OHCE and demonstrate its expression in a second estrogen-responsive tissue, the endometrium, which also expresses CYP1B1 involved in the local formation of 4-OHCE (5). In the uterus of postmenopausal women, we further showed using the UGT2B7 antibody immunoreactivity in the cells that also express CYP1B1, involved in the formation of 4-OHCEs. As for CYP1B1, UGT2B7 staining was predominantly seen in the cytoplasm in epithelial cells lining the uterine glands and those covering the surface in addition to smooth muscle cells of the myometrium (49, 50) . These observations suggest that the formation of genotoxic 4-OHCE by CYP1B1 and subsequent conjugation by UGT2B7 may occur within the same cells of the uterus, supporting the protective role of UGT2B7.
The present study further highlights the previously unrecognized complexity of estrogen metabolism and suggests that the glucuronidation pathway may be significant in estrogen metabolism in extrahepatic tissue such as the mammary gland and uterus. Because E 2 and its 2-OH, 4-OH, and 2-MeO metabolites exert various biological effects, the present findings indicate that the glucuronidation pathway may represent a critical process in uterine cells, thus influencing estrogen exposure in this tissue. In agreement with this hypothesis, we recently demonstrated that a lower expression of UGT1A1, a UGT involved in the conjugation 2-OHCE and 2-MeOCE that mediate proliferative inhibitory effects (11-13), significantly decreases the risk of endometrial cancer (26) . These data suggest that lower expression of UGT1A1 decreases the risk of endometrial cancer by reducing the excretion of the antiproliferative metabolite of E 2 , 2-MeOE 2 , in the endometrium. It is thus predicted from our kinetic data that additional UGTs, such as UGT2B7, play a significant role in protecting locally against 4-OHCEs by reducing their mutagenic potential in estrogenresponsive tissues such as the breast and uterus. In fact, the evaluation of the relative level of expression of the most reactive UGTs toward estrogens in nonmalignant endometrium tissues support the high level of expression of the UGT2B7 isoenzyme in this tissue (data not shown). Altogether, our data highlight the major importance of determining the presence of estrogen glucuronide derivatives in estrogen-sensitive tissues and into circulation.
